Phase 1 Study of LAI MMV055 and MMV371 in Healthy Participants Initiated
A Phase 1 single ascending dose study is underway to evaluate the safety and pharmacokinetics of LAI MMV055 alone and in combination with MMV371 in healthy participants.
Phase I
Infectious Disease / Malaria
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this Phase 1 trial for LAI MMV055 and MMV371 is significant as it may lead to advancements in malaria treatment, positioning Medicines for Malaria Venture as a key player in this therapeutic area. Positive outcomes could enhance partnerships and funding opportunities, impacting the overall development pipeline for malaria therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the safety data and pharmacokinetic results from the initial cohorts, particularly the outcomes of the sentinel dosing.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.